


Compounds of Formula (I) wherein:  $R^1$  is hydroxymethyl;  $R^2$  is selected from  $-C(O)NR^4R^5$ ,  $SO_2NR^4R^5$ ,  $S(O)_pR^4$  and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring;  $R^3$  is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano;  $R^4$  is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2;  $R^5$  is hydrogen or (1-4C)alkyl; or  $R^4$  and  $R^5$  together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.



(I)